Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”
Journal of Gynecologic Oncology · 2024
DOI: 10.3802/jgo.2024.35.e34 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Lilian van Wagensveld und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands. Hauptthemen laut MEDLINE: CA-125 Antigen, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Neoadjuvant Therapy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: DCS, KWF Kankerbestrijding.
Abstract (Originalsprache)
OBJECTIVE: The modeled CA-125 ELIMination rate constant K (KELIM) has been validated as a marker of response to chemotherapy in >12,000 patients with advanced epithelial ovarian carcinoma (EOC) treated in first-line setting enrolled in >12 clinical trials. Patient KELIM is calculable online https://www.biomarker-kinetics.org/presentation. The objective was to investigate the prognostic value of KELIM in a large real-life national cancer registry with non-selected patients. METHODS: We investigated 4,025 EOC patients from the Netherlands Cancer Registry treated with neoadjuvant chemotherapy (NACT) ± followed by interval debulking surgery (IDS). Patient KELIM values were calculated in patients with ≥ 3 CA-125 measurements during NACT. KELIM was standardized with a pre-specified cut-off and scored as unfavorable/favorable (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.
- GROW, School for Oncology and Developmental Biology and Reproduction, Maastricht, The Netherlands. l.vanWagensveld@iknl.nl.
- Faculté de Médecine Lyon-Sud, Université Lyon, Université Claude Bernard Lyon 1, Lyon, France.
- Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- GROW, School for Oncology and Developmental Biology and Reproduction, Maastricht, The Netherlands.
- Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, Maastricht, The Netherlands.
ORCID-Profile: Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa, Gilles Freyer, Gabe S Sonke, Roy F P M Kruitwagen, Benoit You
Förderung
- DCS
- KWF Kankerbestrijding
Zitieren
APA
van Wagensveld, L., Colomban, O., van der Aa, M. A., Freyer, G., Sonke, G. S., Kruitwagen, R. F. P. M., & You, B. (2024). Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e34
Vancouver
van Wagensveld L, Colomban O, van der Aa MA, Freyer G, Sonke GS, Kruitwagen RFPM, et al. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e34
BibTeX
@article{vanWagensveld2024,
author = {van Wagensveld, Lilian and Colomban, Olivier and van der Aa, Maaike A and Freyer, Gilles and Sonke, Gabe S and Kruitwagen, Roy F P M and You, Benoit},
title = {Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”},
journal = {Journal of Gynecologic Oncology},
year = {2024},
doi = {10.3802/jgo.2024.35.e34}
}
EUVIMED